Osteogenic Growth Peptide (OGP)
A 14-aa C-terminal histone H4 fragment circulating naturally in serum; the active short fragment OGP(10-14) (Tyr-Gly-Phe-Gly-Gly) stimulates osteoblast proliferation and bone formation in rodents a… | Compound
Aliases (5)
▸ Overview TL;DR
A 14-aa C-terminal histone H4 fragment circulating naturally in serum; the active short fragment OGP(10-14) (Tyr-Gly-Phe-Gly-Gly) stimulates osteoblast proliferation and bone formation in rodents and accelerates marrow recovery after irradiation/chemotherapy. Promising bench/preclinical profile, almost no human data. NOT-RELEVANT for Dylan.
▸ Mechanism of action
Discovered in 1989 by Bab et al. as the bone-marrow regenerative factor in post-ablation rat marrow. Sequence corresponds to histone H4 residues 90-103. Circulates bound to α2-macroglobulin in inactive complex; released → activated.
Active C-terminal pentapeptide OGP(10-14) [Tyr-Gly-Phe-Gly-Gly] retains all biological activity. Mechanism involves:
- Gi/o-coupled receptor on osteoblasts (receptor identity not fully resolved)
- Downstream activation of MAPK/ERK and PI3K/Akt
- ↑ osteoblast proliferation, alkaline phosphatase, type I collagen, osteocalcin
- Hematopoietic stimulation in marrow stroma — synergistic with G-CSF in animal models
- Antagonizes glucocorticoid-induced bone loss in some models
▸ Pharmacokinetics No data
▸ What to expect Generic
- 1Week 1Tolerability and dose-response.
- 2Week 2-4Early effect window.
- 3Week 4-8Peak benefit assessment.
- 4Week 8+Cycle decision point.
▸ Side effects + safety
- Common (>10% users): Unknown — no real safety data
- Less common: Injection-site reactions
- Rare-serious (<1% but worth knowing):
- Theoretical concern: peptide also affects hematopoiesis — could in principle alter blood counts
- Theoretical concern: any growth factor with mitogenic activity carries hypothetical neoplasia risk if subclinical malignancy present
- Unknown immunogenicity
- Specific watch periods: No clinical guidance exists
▸Interactions2 compounds
- In bench/animal studies:SynergisticG-CSF (hematopoietic synergy), BMPs (additive osteogenic)
- Forum-claimed (low evidence):SynergisticBPC-157, TB-500 for "complete recovery stack" — no rigorous data
▸References4 sources
Bab I, et al. (1992) — Histone H4-related osteogenic growth peptide (OGP): a novel circulating stimulator of osteoblastic activity. EMBO J
1992PMID 1396589, foundational discovery paper
Greenberg Z, et al. (1995) — Mitogenic action of osteogenic growth peptide (OGP): role of amino and carboxy-terminal regions and characterization of primary signal transduction pathways. Biochim Biophys Acta
1995PMID 7669810, mechanism characterization
Gabet Y, et al. (2004) — Osteogenic growth peptide modulates fracture callus structural and mechanical properties. Bone
2004PMID 15268878, fracture-healing animal model
Pigossi SC, et al. (2016) — Role of Osteogenic Growth Peptide (OGP) and OGP(10-14) in Bone Regeneration: A Review. Int J Mol Sci
2016PMID 27669237, comprehensive review